新型流感衍生的HLA-B*18:01受限表位的表征
Samuel Liwei Leong1,2, Lawton Murdolo1,2, Janesha C Maddumage1,2
1Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS) La Trobe University Bundoora VIC Australia.
Clinical & translational immunology
|May 13, 2024
概括
这项研究确定了新型免疫原性流感,限制在HLA-B*18:01,为CD8+T细胞疫苗提供了新的点来对抗流感. 这些发现推动了疫苗设计,以扩大对不同流感菌株的覆盖范围.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 结构生物学 结构生物学
背景情况:
- 尽管有疫苗可用,但季节性流感导致全球显著的死亡率.
- CD8+ T细胞通过向保存的流感蛋白来减少疾病严重程度,提供了一个有希望的疫苗策略.
- 由于特定的-HLA结合偏好,HLA类I多态性对广泛的CD8+T细胞疫苗设计构成了挑战.
研究的目的:
- 为了评估新型流感衍生的免疫性,预计将结合HLA-B*18:01分子.
- 描述这些HLA-B*18:01受限制的结构和免疫特性.
- 为了确定 CD8+ T 细胞介导的流感免疫力潜在的新疫苗点.
主要方法:
- 质谱法用于识别新型流感.
- 用CD8+ T细胞激活测试和蛋白质生物化学来评估的免疫性和HLA限制.
- 使用X射线结晶学来确定这些的HLA-B*18:01的结构.
主要成果:
- 在6种新型中,有3种在HLA-B*18:01阳性个体中表现出免疫性.
- 该研究确定了第一个HLA-B*18:01的晶体结构,呈现出免疫性流感.
- 分析揭示了特征四种的每个特征的特异性T细胞受体谱.
结论:
- 鉴定了从流感矩阵蛋白1中衍生的新型免疫性,非结构性蛋白和RNA聚合酶子单元.
- 这些体代表了潜在的HLA-B*18:01限制疫苗标.
- 这些发现有助于针对不同人群的CD8+ T细胞流感疫苗的合理设计.
相关概念视频
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Antigens Involved in Adaptive Immunity
486
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
486


